Deutsche Bank AG Acquires New Position in CeriBell (NASDAQ:CBLL)

Deutsche Bank AG bought a new position in CeriBell (NASDAQ:CBLL) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 230,787 shares of the company’s stock, valued at approximately $5,973,000. Deutsche Bank AG owned approximately 0.64% of CeriBell at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of CBLL. FMR LLC purchased a new position in CeriBell during the 4th quarter worth $128,120,000. ABG WTT Global Life Science Capital Partners GP Ltd bought a new position in CeriBell in the fourth quarter worth approximately $28,160,000. RA Capital Management L.P. purchased a new stake in CeriBell during the fourth quarter worth $21,340,000. Vanguard Group Inc. bought a new stake in CeriBell during the 4th quarter valued at $18,015,000. Finally, Board of Trustees of The Leland Stanford Junior University bought a new stake in CeriBell during the 4th quarter valued at $16,143,000.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. LADENBURG THALM/SH SH started coverage on CeriBell in a research note on Friday, April 4th. They issued a “buy” rating and a $32.00 target price on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $33.00 price target on shares of CeriBell in a report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $32.50.

Insider Buying and Selling

In related news, CEO Xingjuan Chao sold 5,700 shares of the stock in a transaction that occurred on Thursday, April 17th. The shares were sold at an average price of $15.02, for a total value of $85,614.00. Following the transaction, the chief executive officer now owns 746,451 shares in the company, valued at approximately $11,211,694.02. This represents a 0.76% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 24,700 shares of company stock worth $372,434 in the last 90 days. Insiders own 20.10% of the company’s stock.

CeriBell Trading Up 2.2%

CBLL stock opened at $17.97 on Monday. CeriBell has a 52 week low of $10.01 and a 52 week high of $32.75. The firm has a 50 day moving average of $17.50 and a 200 day moving average of $22.35.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The company had revenue of $20.49 million during the quarter, compared to analysts’ expectations of $19.30 million. As a group, analysts predict that CeriBell will post -2.46 EPS for the current fiscal year.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.